A number of therapeutic uses of cannabis and its derivatives have been postulated from preclinical investigations. Possible clinical indications include spasticity and pain in multiple sclerosis, cancer-associated nausea and vomiting, cancer pain and HIV neuropathy. However, evidence is limited, may reflect subjective rather than objective outcomes, and is not conclusive. Controversies lie in how to produce, supply and administer cannabinoid products. Introduction of cannabinoids therapeutically should be supported by a regulatory and educational framework that minimises the risk of harm to patients and the community. The Regulator of Medicinal Cannabis Bill 2014 is under consideration in Australia to address this. Nabiximols is the only cannabinoid on the Australian Register of Therapeutic Goods at present, although cannabidiol has been recommended for inclusion in Schedule 4.
Keywords: cannabidiol; drug regulation; medical marijuana; nabiximols.
Conflict of interest statement
Conflict of interest: none declared
Cannabinoids for Treatment of MS Symptoms: State of the EvidenceJ Rice et al. Curr Neurol Neurosci Rep 18 (8), 50. PMID 29923025. - ReviewTwo recent high-quality systematic reviews concluded that the only strong evidence for medical marijuana in neurological disorders was for reducing the symptoms of patien …
Medical Use of Cannabis Products: Lessons to Be Learned From Israel and CanadaJ Ablin et al. Schmerz 30 (1), 3-13. PMID 26767992.The use of standardized, synthetic, and plant-based cannabis products should be allowed in Germany for defined medical conditions when high-level evidence of efficacy and …
[Systematic Review of Safeness and Therapeutic Efficacy of Cannabis in Patients With Multiple Sclerosis, Neuropathic Pain, and in Oncological Patients Treated With Chemotherapy]L Amato et al. Epidemiol Prev 41 (5-6), 279-293. PMID 29119763. - Reviewthere is incomplete evidence of the efficacy and safety of medical use of cannabis in the clinical contexts considered in this review. Furthermore, for many of the outcom …
Randomised Controlled Trial (RCT) of Cannabinoid Replacement Therapy (Nabiximols) for the Management of Treatment-Resistant Cannabis Dependent Patients: A Study ProtocolAK Bhardwaj et al. BMC Psychiatry 18 (1), 140. PMID 29776349.Australian and New Zealand Clinical Trial Registry: ACTRN12616000103460 (Registered 1st February 2016).
Medical Marijuana Patient Counseling Points for Health Care Professionals Based on Trends in the Medical Uses, Efficacy, and Adverse Effects of Cannabis-Based Pharmaceutical DrugsJR Parmar et al. Res Social Adm Pharm 12 (4), 638-54. PMID 26443472. - ReviewThe purpose of this report is to present a review of the medical uses, efficacy, and adverse effects of the three approved cannabis-based medications and ingested marijua …
Cited by 2 PubMed Central articles
Assessment of Cannabinoids Agonist and Antagonist in Invasion Potential of K562 Cancer CellsF Gholizadeh et al. Iran Biomed J 23 (2), 153-8. PMID 29883990.Our findings clarifies that CB1 receptors are responsible for anti-invasive effects in the K562 cell line.
β-Caryophyllene and β-Caryophyllene Oxide-Natural Compounds of Anticancer and Analgesic PropertiesK Fidyt et al. Cancer Med 5 (10), 3007-3017. PMID 27696789. - ReviewNatural bicyclic sesquiterpenes, β-caryophyllene (BCP) and β-caryophyllene oxide (BCPO), are present in a large number of plants worldwide. Both BCP and BCPO (BCP(O)) pos …